drugset / Trial / NCT05074121
NAC for Attenuation of COVID-19 Symptomatology
Phase 2
Unknown
200 enrolled
Cambridge Health Alliance
Alturix · collabThe Thoracic Foundation · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The objective of this study is to determine whether oral NAC is effective at attenuating COVID-19 disease symptom severity and duration of symptoms.
Timeline
- Start
- 2024-03-31
- Primary completion
- 2024-12-31
- Completion
- 2025-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | N-acetylcysteine | Small molecule | 1200 mg | Oral |